Christopher John Kenney Sells 1,410 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the transaction, the insider owned 7,069 shares of the company’s stock, valued at $390,420.87. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Christopher John Kenney also recently made the following trade(s):

• On Tuesday, March 10th, Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81.

Xenon Pharmaceuticals Stock Performance

Shares of XENE opened at $55.23 on Friday. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95. The firm’s 50 day moving average price is $43.71 and its two-hundred day moving average price is $41.94. The firm has a market cap of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the company earned ($0.84) EPS. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new position in Xenon Pharmaceuticals in the fourth quarter valued at approximately $1,125,000. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth $55,000. Mackenzie Financial Corp acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth $210,000. ADAR1 Capital Management LLC lifted its stake in Xenon Pharmaceuticals by 7.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after acquiring an additional 14,871 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $964,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

XENE has been the topic of a number of research reports. Guggenheim restated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Deutsche Bank Aktiengesellschaft boosted their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Needham & Company LLC upped their price target on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Robert W. Baird lifted their price objective on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Finally, Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $71.94.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.